Wengbai Jiedu Tablets Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as a multi-dosage-form active pharmaceutical ingredient rather than a finished veterinary medicinal product. No harmonised international model designation is published for this descriptor; the product is identified by the complete name and the manufacturer’s grade code appearing on the certificate of analysis. The physical form of the supplied material is manufacturer-specific and must be confirmed on the CoA, with the common commercial presentation being a milled or micronised solid. The material is intended for downstream incorporation into tablets, capsules, powders, granules, premixes, solutions, and injectable liquids, provided that each dosage-form pathway is re-validated for the specific batch and target species. The designation “Veterinary Grade” indicates that residual solvent, elemental impurity, microbial enumeration, and stability data are controlled under veterinary GMP documentation rather than under a human pharmacopoeial monograph. Published data for this exact multi-dosage-form configuration is limited; if a national veterinary pharmacopoeia monograph exists, it supersedes the general framework described below, but in its absence the manufacturer’s release docket should be treated as the controlling specification.

What Specifications Govern Release of a Multi-Dosage-Form Veterinary API?

Because no public monograph specific to Wengbai Jiedu Tablets was identified in commonly referenced compendia at the time of writing, release and stability specifications are derived from the vendor’s dossier and from the general veterinary API control framework. The following quality attributes are typically controlled for non-sterile botanical APIs intended for solid and liquid downstream processing. Exact limits must be confirmed on each batch CoA; the ranges shown are common acceptance windows for botanical multi-component APIs, not product-specific claims.

On a production rotary tablet press equipped with a forced feeder, the main conflict is between particle-size reduction for content uniformity and the loss of flowability caused by cohesive fines. A milled botanical API with D90 above 150 µm frequently produces weight variation because coarse particles segregate during bin blending and die filling. Reducing D90 to 75 µm improves blend homogeneity but can produce hopper bridging, feed-frame accumulation, and sticking when loss on drying exceeds 5.0% or when the powder residence time in the feed frame exceeds 30 min under high ambient humidity. Compression failure modes at precompression forces above 6 kN are typically capping and lamination when un-compacted fines exceed 30% of total tablet mass. Blend uniformity is verified according to USP <905> or Ph. Eur. 2.9.40, while moisture is determined by USP <731>. Capsule filling on tamping-pin or dosator machines is stable when the API bulk density is 0.35–0.65 g/mL; fill-weight drift is most commonly caused by segregation of particles above 250 µm.

Particle-Size Limits, Flow Function, and Segregation Risk in Solid Dosage Manufacture

Particle-size distribution is the central quality attribute for all non-injectable solid dosage forms. Laser diffraction data are generated according to ISO 13320:2020; vendors should report D10, D50, and D90 rather than a single mean diameter. The following table presents representative downstream criticality targets used for multi-dosage-form botanical APIs; values must be confirmed against the vendor’s method validation because no monograph fixed for this specific product is publicly available.

Granulation is not required for every formulation. When the dose exceeds 100 mg and the tablet mass exceeds 300 mg, dry blending followed by direct compression is generally adequate if the Hausner ratio remains below 1.25 and the D10 remains above 10 µm to limit dust. Wet granulation becomes necessary when the formulation contains a highly hygroscopic premix or when the API particle size must be intentionally enlarged to reduce segregation. In medicated premixes, the API is dispersed on a carrier such as ground corncob or lactose monohydrate. Carrier adhesion is controlled by the median particle-size ratio; a ratio of 1:10 to 1:30 between API and carrier median diameters is common in vertical screw mixers. Segregation during bulk transport occurs when the API D90 exceeds 250 µm and the carrier D50 is below 300 µm, particularly at fill heights above 70% of mixer capacity. For field use, this means the premix grade should not automatically be milled to tablet-grade particle size, because over-milling increases dust exposure and may reduce carrier adhesion.

When the API Pathway Is Directed to Injectable Solutions

For parenteral manufacture, the same chemical material must meet a different and more restrictive control profile. The general veterinary-grade powder is not inherently sterile, and a solid-grade CoA may not include bacterial endotoxin data. Injectable use is therefore not permissible solely on the basis of chemical assay. Bacterial endotoxin limit is calculated as K/M, where K is the threshold pyrogenic dose for the target species in EU/kg and M is the maximum dose in mg/kg. For a K value of 5 EU/kg and an M value of 10 mg/kg, the resulting limit is 0.5 EU/mg. If the dose is reduced or the species-specific K value is tighter, the limit tightens proportionally. Species-specific K values should be justified from regulatory guidance; published data for this specific product is limited. Pre-sterilisation bioburden should be maintained at or below 100 CFU/g because terminal sterilisation efficacy is logarithmic and cannot compensate for high initial contamination without damaging heat-labile constituents. Aqueous solutions after reconstitution are typically filtered through a 0.22 µm PVDF or PES membrane; if undissolved botanical particulates above the nominal pore size remain, the filter loading can exceed 20 L/m² before flux decline becomes operationally unacceptable. Moist-heat terminal sterilisation at 121°C for 15 min may degrade heat-labile constituents; alternative F0 values below 8 min must be justified by stability data. Pre-formulation solubility should be examined from pH 3.0 to 8.0, and precipitation of polyphenolic constituents is commonly observed above pH 8.0. The absence of compatibility data for this exact mixture requires binary pH and precipitation studies before first pilot batch.

Non-sterile oral or topical solutions require less restrictive bioburden control, but the API must still be free of solvent residues that would be unacceptable in a dosed liquid. The manufacturing sequence typically begins with pre-wetting the API in a small volume of ethanol or propylene glycol before aqueous dilution; this step reduces clumping when the D90 is below 20 µm. Dissolution for finished solutions is evaluated by USP <711> or Ph. Eur. 2.9.3, but for API suspensions, wettability and dispersion are more critical than intrinsic solubility. Long-term aqueous stability is pH-sensitive; a preservative system compatible with the botanical matrix, such as benzoic acid or potassium sorbate, should be challenged by USP <51> antimicrobial effectiveness testing.

Comparative Boundaries Against Technical-Grade Botanicals and Single-Dosage APIs

The main difference between this product and a technical-grade botanical powder is not chemical assay but the presence of veterinary GMP documentation, controlled residual solvents, and microbial limits. Technical-grade botanicals may pass visual identification but fail USP <561> heavy-metals limits or VICH GL18 residual solvent criteria because they are extracted with solvent systems not intended for veterinary drug use. Single-dosage APIs are usually optimised for one route only; a multi-dosage-form veterinary API is released with a broader control profile but cannot automatically enter every route without route-specific validation. The same lot may be suitable for tablets or premixes but unsuitable for injectable manufacture if bioburden is above 100 CFU/g or if endotoxin data are absent. The phrase “Veterinary Grade API for Injections” therefore requires a separate injectable-grade definition, not merely a multi-route label. This is the main operational distinction from ordinary oral-grade APIs and from technical-grade feed additives.

Cross-Contamination Control in Medicated Premix Lines Is the Binding Constraint

On production lines that process both medicated and non-medicated feeds, the limiting operational parameter is carryover. Fluid-bed dryers and ribbon blenders should be qualified for removal of the API to a pre-defined maximum allowable carryover. Visual cleanliness alone is insufficient because low-level residues may remain below visual detection. Swab and rinse sampling with HPLC analysis is used to quantify residues. If the same line is used for multiple animal species, a species-specific carryover limit based on the lowest intended dose and the target animal safety factor is calculated. No universal limit is published for this specific botanical mixture; local feed-safety authorities may require a conservative carryover limit of 0.1% of the lowest labelled dose unless justified by a site-specific cleaning validation. Cleaning validation should be performed under the same GMP expectations as FDA 21 CFR 211.67 or equivalent national rules. The absence of published cleaning data for this exact API means the first production campaign must include recovery studies on all product-contact surfaces.